A new option for adults who have experienced stroke will now be available to further reduce future risk.
News|Articles|October 6, 2003
New Product Newswire
New Product Newswire
Advertisement
Advertisement
Related to this article
Findings from a meta-analysis of over 125 clinical trials led the agency to require a class-wide label change.
Gilead’s current lenacapavir patent is what makes Dr Reddy’s Laboratories’ formulation tentative.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Asundexian, First FXIa Inhibitor for Stroke Prevention
2
The Outcome-Based Program That Could Reshape Pharmacists’ Roles
3
High Triglycerides Independently Linked with Severe COVID-19 Death
4
US Lost Over 3000 Pharmacies From 2022 to 2024, Mostly Chains
5